U.S. Analgesics Market - Databook 2025 to 2034

The U.S. analgesics market size was estimated at USD 17.03 billion in 2024 and is projected to be worth around USD 28.49 billion by 2034, growing at a CAGR of 5.28% from 2025 to 2034.

Highlights of the U.S. Analgesics Market

• By drug class, the opioids segment held a dominant presence in the U.S. analgesics market in 2024.
• By drug class, the NSAIDs segment is expected to grow at the fastest rate in the market during the forecast period of 2025 to 2034.
• By indication, the surgical pain segment accounted for a considerable share of the U.S. analgesics market in 2024.
• By indication, the neuropathic pain segment is projected to experience the highest growth rate in the market between 2025 and 2034.
• By type, the prescription segment led the U.S. analgesics market.
• By type, the OTC segment is set to experience the fastest rate of the market growth from 2025 to 2034.
• By pain type, the surgical and trauma pain segment registered its dominance over the U.S. analgesics market in 2024.
• By pain type, the musculoskeletal pain segment is anticipated to grow at the highest CAGR in the market during the studied years.
• By application, the internal analgesics segment dominated the U.S. analgesics market.
• By application, the external analgesics segment is projected to expand rapidly in the market in the coming years.
• By route of administration, the oral segment maintained a leading position in the U.S. analgesics market in 2024.
• By route of administration, the parenteral segment is predicted to witness significant growth in the market in the coming years.

Industry Valuation and Growth Rate Projection

Analgesics refer to a type of medication used to relieve pain. It can be either an opioid or a non-opioid medication, and its use can be measured in terms of frequency. An analgesic drug, also known as a painkiller, pain reliever, antalgic, or analgesic, is any member of the group of drugs used for pain management. An agent producing diminished sensation to pain without loss of consciousness: a drug that is used to relieve pain and produce analgesia. Regulatory support, increasing demand, and technological advancements are driving the growth of the analgesics market.

The U.S. analgesics market includes a wide range of applications, including its use in the management and treatment of pain. They include many classes of medicines, opioids, local anaesthetics, antidepressants, non-steroidal anti-inflammatory drugs, and acetaminophen. They work either by reducing inflammation or by changing the way the brain processes and perceives pain. Topical analgesic drugs are used to treat both chronic pain and acute pain.

Market Trends

• Technological advancements in drug delivery: Recent advancements in pain management based on nanoparticles include nanoparticles designed for analgesic drugs and nanocarriers. Sustained release and targeted delivery of analgesic drugs remain a critical problem for effective control of pain. The use of nanocarriers has been suggested to enhance the effective delivery of these agents to target sites while reducing side effects.
• Regulatory support: Implementing a comprehensive regulatory compliance program can help avoid fines and penalties. Regulatory compliance improves a company’s business performance and competitive advantage by enhancing operational efficiency, promoting workplace safety, increasing resilience, and boosting profitability.
• Rising senior population: Acetaminophen (aka, paracetamol) is the recommended first-line therapy among older adults for mild to moderate pain by the American Geriatric Society (AGS). Topical analgesics are also widely prescribed for pain management among the elder population. When common pain medicines don’t work to manage pain, the healthcare provider can suggest other medicines, like anticonvulsants or antidepressants.

Restraints

• Lengthy approval processes: The approval limits in processes refer to the restrictions on the steps and the approvers in an approval process. A standard approval process may contain up to 30 steps, with every step can have up to 25 unique approvers. These long processes lead to delayed availability of these drugs for the general population.
• Side effects and safety concerns: Analgesics also come with several side effects including but not limited to heartburn, upset stomach, or nausea, tinnitus, progressive deafness, and stomach ulcers. Anyone who takes opioid prescriptions can develop opioid dependency which has largely been linked to the opioid crisis ongoing in the United States.

Opportunity

Rise in telehealth and digital health platforms: The benefits of digital health technologies include increased operational efficiency at health facilities like hospitals, enhanced patient outcomes through personalized treatment plans, decreased treatment costs for both providers and patients, and expanded access to historically marginalized communities. In telehealth, patients do not have to travel to a healthcare provider’s office or clinic, walk, park, or sit in a waiting room when we are sick. Many patients benefit from telehealth, including elderly patients, rural patients, paediatric patients, and their families.

Recent Developments in the U.S. Analgesics Market:

• In January 2025, the United States Food and Drug Administration approved a new non-opiod painkiller called suzetrigine. The medication is being manufactured by Vertex Pharmaceuticals, under the brand name Journavx.
• In October 2023, the approval of a potent non-opioid painkiller in the United States was announced by a pharmaceutical company headquartered in Belgium, Hyloris Pharmaceuticals.